Enterprise-grade imaging and precision endpoints for clinical trials .
Our vision is to accelerate the time to impact of new life-saving therapies in lung and heart disease.
Qureight is a tech-first, AI-powered imaging CRO. We deliver our suite of products through a proprietary data and imaging curation platform. This permits the analysis of clinical imaging and other healthcare data from patients with lung and heart disease, helping our customers bring treatments to market, faster. We provide automated image management and AI analysis in therapeutic areas such as Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Hypertension and Bronchiectasis.
Our AI-powered data and imaging curation platform permits the analysis of clinical imaging and other healthcare data from patients with lung and heart disease
An end-to-end imaging CRO
We offer three main services at Qureight
Workflow
Our imaging platform has workflow tools to improve image handling in clinical trials, accelerating patient inclusion through a proprietary infrastructure that leverages AI and study inclusion/exclusion decisions to rapidly onboard sites and evaluate patients in days, not weeks.
AI Lung
Our best-in-class proprietary lung image biomarkers (Lung8TM, Air8TM, Fibr8TM Glass8TM and Vascul8TM) were developed with deep learning (3D – Deep Learning Models) to identify five key structural changes in the lung that can indicate disease progression during a clinical trial, in response to a drug.
Synthetic Control Arms
Our unique healthcare access through data contracts across the UK NHS and around the world has allowed us to build up some of the largest data sets globally in diseases including Idiopathic Pulmonary Fibrosis, connective tissue diseases and Pulmonary Hypertension. We use the data to build synthetic control arms that are carefully matched to existing drug or placebo trial arms.
Our current therapeutic areas
Interstitial Lung Diseases
Interstitial lung diseases (ILDs) are a group of lung disorders that cause inflammation and/or scarring of the lung tissue. They can be difficult to diagnose and monitor, and clinical trial development pathways are complex. There is an urgent unmet need for biomarkers that reliably predict disease behaviour, inform management decisions and accelerate treatment trials.
ILDs encompass over 200 distinct diseases, including Idiopathic Pulmonary Fibrosis and Connective Tissue Disease–associated ILD (CTD-ILD). Across multiple ILD diagnoses, some patients develop a progressive fibrosing phenotype where disease worsens over time despite therapy. Treatment varies by underlying diagnosis and disease behaviour, from immunomodulatory therapy to antifibrotics. Some patients may develop pulmonary hypertension, and a minority ultimately require lung transplantation.
Pulmonary Hypertension
Pulmonary Hypertension (PH) is an umbrella term for conditions defined by elevated pressure in the pulmonary circulation (the blood vessels between the heart and lungs). It can be driven by lung disease, left heart disease, chronic blood clots, autoimmune/connective tissue disease, or be of unknown cause.
Monitoring PH is difficult and often relies on invasive right heart catheterisation to directly measure pressures. There is a strong need for robust non-invasive ways to assess severity, stratify patients for trials, and detect treatment response over time. A new generation of PH therapies is now being developed by multiple biopharma companies.
Bronchiectasis
Bronchiectasis is a chronic lung condition characterised by the permanent widening (dilation) and thickening of the bronchi (the airways in the lungs). This damage prevents the airways from effectively clearing mucus, leading to mucus retention, frequent lung infections, and inflammation. Treatment focuses on managing symptoms, preventing infections, and improving quality of life – often involving antibiotics, airway clearance techniques, and sometimes surgery. Novel imaging biomarkers are being developed to support trial design (patient stratification and endpoint selection) and improve patient management by enabling more objective, reproducible assessment of disease severity and treatment response.
Trusted by our customers to help them develop life-saving therapies
"Qureight is becoming a real powerhouse in understanding lung fibrosis and related pathological lung processes. Our collaboration helps us gain key insights regarding patient characteristics and drug effects on fibrosis and lung vasculature, and showing how Buloxibutid works in IPF."
MD PhD, Chief Medical Officer, Vicore
"Given the complex nature of PPF, we've made it a priority to leverage cutting-edge technology to measure treatment response in our ongoing MIST study. This collaboration with Qureight will allow us to measure changes in fibrosis volume more sensitively while also enabling us to quantify changes across multiple compartments of the lung."
MD, FCCP, Chief Medical Officer
"Qureight delivered our first qualified imaging site just 2–3 weeks after study contract. The science is excellent — and the people may be even better. I give them my highest recommendation."
MD, CMO, acting Chief Medical Officer
Join us
Accelerating clinical trials is a complex challenge. Our team is uniquely built for this multidisciplinary task.
We hire professionals across a range of career stages in software engineering, devops, data science, machine learning, quality assurance, regulatory affairs, and clinical operations. What unites us is our open culture, continuous learning mindset, and shared mission to accelerate clinical trials and bring therapies to patients faster.
